NewAmsterdam Pharma (NAMS) Depreciation & Amortization (CF) (2023 - 2026)
NewAmsterdam Pharma (NAMS) posted Depreciation & Amortization (CF) of $62000.0 for Q1 2026, up 5.08% sequentially from $59000.0 in Q4 2025, and up 19.23% YoY from $52000.0 in Q1 2025.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Depreciation & Amortization (CF) for 4 years, with the latest figure at $62000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 19.23% year-over-year to $62000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $230000.0 (up 53.33% YoY) and the FY2025 annual result came in at $220000.0, up 94.69% from the prior year.
- Depreciation & Amortization (CF) advanced to $62000.0 in Q1 2026 per NAMS's latest filing, from $59000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $64000.0 in Q3 2025 and troughed at $9000.0 in Q1 2023.
- A 4-year average of $35916.7 and a median of $36500.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) soared 292.31% in 2024, then increased 15.69% in 2025.
- Over 4 years, Depreciation & Amortization (CF) stood at $13000.0 in 2023, then jumped by 292.31% to $51000.0 in 2024, then climbed by 15.69% to $59000.0 in 2025, then advanced by 5.08% to $62000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $62000.0, $59000.0, and $64000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | NewAmsterdam Pharma | 3.13 Bn | 3.13 Bn | - | 59,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59,000.00 |
| Mar 31, 2026 | 62,000.00 |
| Dec 31, 2025 | 59,000.00 |
| Sep 30, 2025 | 64,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Mar 31, 2025 | 52,000.00 |
| Dec 31, 2024 | 51,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Mar 31, 2023 | 9,000.00 |